Friday, June 23, 2017

Drugs in Clinical Pipeline: Erenumab | AMG 334 | Prevention of Migraines | CGRP Receptor Antagonist Monoclonal Antibody

Erenumab (AMG 334) is the first human monoclonal antibody antagonist against the Calcitonin Gene-Related Peptide Receptor (CGRP) receptor. Like the small-molecule CGRP-receptor antagonists, Erenumab fully antagonizes CGRP-receptor function and is dose-dependently effective in an in vivo target coverage model that exhibits translatability to humans.

Erenumab fully inhibited CGRP-stimulated cAMP production with an IC50 of 2.3 nM in cell-based functional assays (human CGRP receptor) and was 5000-fold more selective for the CGRP receptor than other human calcitonin family receptors, including adrenomedullin, calcitonin, and amylin receptors.

Monday, February 27, 2017

Drugs in Clinical Pipeline: AL-3778 I Treatment for Hepatitis B Virus (HBV) | Antivirals Agents


AL-3778 (also known as ALS-003778; JNJ-63595948; NVR-1221; NVR-3-778) is an experimental drug being developed by Alios BioPharma, Inc. to treat Hepatitis B virus (HBV) infection . Hepatitis B is an infectious disease caused by the hepatitis B virus which affects the liver. It can cause both acute and chronic infections. The virus is transmitted by exposure to infectious blood or body fluids. Infection around the time of birth or from contact with other people's blood during childhood is the most frequent method by which hepatitis B is acquired in areas where the disease is common. In areas where the disease is rare, intravenous drug use and sexual intercourse are the most frequent routes of infection.


Treatment for Hepatitis B Virus (HBV)
A New Drug for the Treatment for Hepatitis B Virus (HBV)

Friday, February 24, 2017

Drugs in Clinical Pipeline: MCLA-117 | CLEC12AxCD3 Bispecific Immunoglobulin G (IgG) | Bispecific Antibody I Treatment for Acute Myleoid Leukemia (AML)


MCLA-117 is a full length human CLEC12AxCD3 bispecific immunoglobulin G (IgG) that incorporates CH2 region amino acid substitutions to abrogate Fcγ receptor and C1q interactions while retaining its binding to FcRn. MCLA-117 binds to CD3, a cell-surface molecule present on all T cells, and CLEC12A, a cell surface molecule present on Acute Myleoid Leukemia (AML) cells and stem cells. MCLA-117 is designed to recruit and activate T-cells to kill CLEC12A-expressing AML tumor cells and stem cells, which may prevent recurrence of tumors. MCLA-117 redirects patient's cytotoxic T cells to induce AML tumor lysis.